Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2026)

Amneal Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 2772.46% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 224.1% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 69.84% from the prior year.
• Other financing activities improved to $2.0 million in Q1 2026 per AMRX's latest filing, from -$73.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $73.2 million in Q3 2025 and bottomed at -$73.0 million in Q4 2025.
• The 5-year median for Other financing activities is $139500.0 (2022), against an average of $443500.0.
• Biggest YoY gain for Other financing activities was 7200.9% in 2025; the steepest drop was 48452.98% in 2025.
• Year by year, Other financing activities stood at $423000.0 in 2022, then sank by 89.83% to $43000.0 in 2023, then surged by 251.16% to $151000.0 in 2024, then slumped by 48452.98% to -$73.0 million in 2025, then soared by 102.71% to $2.0 million in 2026.
• Per Business Quant, the three latest AMRX Other financing activities figures stand at $2.0 million (Q1 2026), -$73.0 million (Q4 2025), and $73.2 million (Q3 2025).